18.62
price down icon1.01%   -0.19
after-market Dopo l'orario di chiusura: 18.80 0.18 +0.97%
loading

Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie

pulisher
02:55 AM

Sentiment analysis tools applied to Tonix Pharmaceuticals Holding Corp.July 2025 Sector Moves & Safe Entry Point Alerts - newser.com

02:55 AM
pulisher
07:34 AM

Tonix Pharmaceuticals (TNXP) Showcases Promising Vaccine Data at - GuruFocus

07:34 AM
pulisher
07:33 AM

Tonix advances mpox vaccine candidate TNX-801 with promising data - Investing.com

07:33 AM
pulisher
07:10 AM

Tonix advances mpox vaccine candidate TNX-801 with promising data By Investing.com - Investing.com UK

07:10 AM
pulisher
07:00 AM

14‑Month durability: Tonix TNX-801 single‑dose mpox vaccine protects across multiple preclinical models - Stock Titan

07:00 AM
pulisher
Oct 15, 2025

Tonix Pharmaceuticals Holding Corp. stock retracement – recovery analysisEarnings Growth Report & Pattern Based Trade Signal System - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How to recover losses in Tonix Pharmaceuticals Holding Corp. stockWeekly Volume Report & Short-Term High Return Strategies - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Using portfolio simulators with Tonix Pharmaceuticals Holding Corp. includedQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Automated trading signals detected on Tonix Pharmaceuticals Holding Corp.2025 EndofYear Setup & Risk Managed Investment Signals - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Tonix CEO presents anti-CD154 antibody research at Japan transplant congress - Investing.com Nigeria

Oct 14, 2025
pulisher
Oct 14, 2025

Tonix Pharmaceuticals (TNXP) Highlights Advancements in Transpla - GuruFocus

Oct 14, 2025
pulisher
Oct 14, 2025

How Tonix Pharmaceuticals Holding Corp. stock performs after earningsJuly 2025 Movers & High Yield Equity Trading Tips - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Tonix Pharmaceuticals Presented an Update on Fc-modified - GlobeNewswire

Oct 14, 2025
pulisher
Oct 14, 2025

Phase 1 safety & biomarker data lead Tonix's TNX-1500 toward Phase 2 for kidney transplant prevention - Stock Titan

Oct 14, 2025
pulisher
Oct 13, 2025

Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

Backtesting results for Tonix Pharmaceuticals Holding Corp. trading strategiesWeekly Market Outlook & Daily Profit Focused Screening - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Tonix Pharmaceuticals Holding Corp. stock daily chart insightsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Weiss Ratings Reaffirms Sell (E+) Rating for Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK - Barchart.com

Oct 09, 2025
pulisher
Oct 09, 2025

Fibromyalgia Market Expected to Gain Momentum Through 2034, - openPR.com

Oct 09, 2025
pulisher
Oct 09, 2025

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - The Manila Times

Oct 09, 2025
pulisher
Oct 09, 2025

Tonix Pharmaceuticals to Present at World Vaccine Congress–Europe 2025, Featuring Discussions on TNX-801 Mpox Vaccine - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AI2025 Sector Review & Real-Time Buy Signal Notifications - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

What analysts say about Tonix Pharmaceuticals Holding Corp stockResistance Breakout Alerts & Affordable Growth Strategies - earlytimes.in

Oct 08, 2025
pulisher
Oct 07, 2025

Tonix Pharmaceuticals (TNXP) Plans New Phase 2 Trials for Key Tr - GuruFocus

Oct 07, 2025
pulisher
Oct 07, 2025

Tonix Pharma Plans Phase 2 Trial for 2026 - TipRanks

Oct 07, 2025
pulisher
Oct 07, 2025

Tonix to advance cyclobenzaprine into phase 2 for depression - Seeking Alpha

Oct 07, 2025
pulisher
Oct 06, 2025

Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart models2025 Investor Takeaways & Daily Price Action Insights - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp.2025 Valuation Update & Safe Capital Growth Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futureWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell" - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Tonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi Syndrome - Proactive financial news

Oct 03, 2025
pulisher
Oct 02, 2025

Tonix Pharma Appoints New Head of Market Access - MSN

Oct 02, 2025
pulisher
Oct 01, 2025

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - Sahm

Oct 01, 2025
pulisher
Oct 01, 2025

Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria

Oct 01, 2025
$37.01
price up icon 1.84%
$87.57
price up icon 0.30%
$33.17
price up icon 1.28%
$105.14
price up icon 0.06%
biotechnology ONC
$316.42
price down icon 0.50%
$165.76
price up icon 1.57%
Capitalizzazione:     |  Volume (24 ore):